Transforming medicine and changing lives


May 2, 2024

AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting 2024

Research Triangle Park, N.C.– MAY 2, 2024 – Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, will deliver nine presentations offering insights into its adeno-associated virus (AAV) research and development, a key area of gene therapy focus for the company, at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, which takes place May 7–11, 2024, in Baltimore, Maryland, USA. Presentations will focus on AAV immune-mediated responses as well as the results from the ongoing Phase 1 clinical trial of AB-1002 gene therapy in patients with advanced heart failure. Luke Roberts, MBBS, PhD, Medical Director for Clinical Development at AskBio, will deliver an oral presentation sharing new clinical data from the company’s ongoing Phase 1 trial of AB-1002 in patients with advanced heart failure. This follows AskBio’s recent news that AB-1002 was granted FDA Fast Track Designation for the treatment of congestive heart failure (CHF). AB-1002 (also known as NAN-101) is an investigational gene therapy that has not yet received marketing authorization, and its efficacy and safety have not been established or fully evaluated. AskBio previously communicated that the delivery of AB-1002 was well tolerated and resulted in positive preliminary efficacy outcomes in some patients with non-ischemic CHF and may validate that the AAV2i8 vector capsid used is highly cardiotropic when administered as a single intracoronary infusion at relatively low doses. Preliminary data from the Phase 1 trial of AB-1002 were presented at the 2023 American Heart Association Scientific Sessions in November, and AskBio began enrolling patients in its Phase 2 GenePHIT study of AB-1002 in adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms in January 2024. AskBio’s ASGCT presence will also include key presentations showcasing the company’s continued commitment to optimizing AAV as a gene therapy, with a focus on preventing or reducing AAV immune response-related adverse events, which remains a vital area of investigation across the gene therapy treatment landscape. Attendees can look forward to an ASGCT spotlight speaker presentation on current immune modulation strategies given by Shari Gordon, PhD, Senior Director of Immunology at AskBio, on Day 3. On Day 4, Shari Gordon will deliver on behalf of Audry Fernandez, PhD, Principal Scientist & Group Lead, Immunology R&D at AskBio, an oral presentation on pre-clinical research into AAV-specific immune responses, and Liujiang Song, PhD, Principal Scientist for R&D Capsid and Biology at AskBio, will offer insights into AAV biology and vector intracellular fate during an oral presentation on AAV episome configuration using third generation long-read sequencing technologies and advanced bioinformatics. “Our presence at ASGCT this year highlights our continued commitment to sharing AAV developments with the gene therapy community. Covering clinical and pre-clinical research, our presentations show our robust progress and ongoing ambition to bring to patients transformative therapies that were once unthinkable,” said Gustavo Pesquin, Chief Executive Officer, AskBio. “With our clinical and early-stage programs advancing, these are exciting times at AskBio.” With an ambitious the news

We are on a never-ending quest to advance genetic technology

and life-saving AAV gene therapy

In 1984, Dr. Jude Samulski, one of AskBio’s visionary founders, asked if a virus could be used to erase genetic disease. Discovering the answer cleared the path for historic advances in genetic medicine, and AskBio is helping to lead the way.

Learn about AskBio »

gene therapy

Revolutionizing gene therapy

Cures for life-altering diseases depend on new technology to lower the cost of treatment and increase supply for every patient who needs it.

Explore our technology »

Clinical Pipeline

Changing lives

Our clinical pipeline is the direct result of listening to patients, their families, their care teams and disease-advocacy organizations.

Discover our pipeline »

Putting patient care first

The voices of patients drive everything we do. They propel our research and the urgent need to find cures.

For Patients »

Work with us

Advancing research

Today’s genetic discoveries are some of the most awe-inspiring advances in medical history. We welcome collaboration with innovative minds in genetic R&D.

Building careers

Help transform the face of healthcare with life-changing gene therapy. Every life enriched by our scientific advancements is a result of someone like you.


There are no upcoming events.